Stockscreener 앱 받기
779.53
0.53%
4.08
시장 영업 전:
777.70
-1.83
-0.23%
전일 마감가:
$775.45
열려 있는:
$778.54
하루 거래량:
3.04M
Relative Volume:
0.77
시가총액:
$724.64B
수익:
$49.00B
순이익/손실:
$11.11B
주가수익비율:
63.43
EPS:
12.29
순현금흐름:
$-1.27B
1주 성능:
+1.15%
1개월 성능:
+5.67%
6개월 성능:
+0.98%
1년 성능:
-13.90%
1일 변동 폭
$774.00
$785.00
1주일 범위
$763.02
$802.50
52주 변동 폭
$677.09
$972.53
일라이 릴리 Stock (LLY) Company Profile
명칭
Lilly Eli Co
전화
(317) 276-2000
주소
LILLY CORPORATE CTR, INDIANAPOLIS, IN
LLY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
779.53 | 724.64B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
152.75 | 376.43B | 89.33B | 21.81B | 18.57B | 8.99 |
|
NVO
Novo Nordisk Adr
|
69.02 | 352.49B | 43.59B | 15.04B | 10.74B | 3.3766 |
|
ABBV
Abbvie Inc
|
185.62 | 334.73B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
121.01 | 234.21B | 53.22B | 12.86B | 14.85B | 6.39 |
일라이 릴리 Stock (LLY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-05 | 다운그레이드 | Erste Group | Buy → Hold |
| 2025-04-28 | 다운그레이드 | HSBC Securities | Buy → Reduce |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-10 | 재개 | BofA Securities | Buy |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-09-13 | 재개 | Citigroup | Buy |
| 2024-08-12 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-02-21 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2024-02-16 | 재확인 | Morgan Stanley | Overweight |
| 2023-12-21 | 다운그레이드 | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-10-20 | 재개 | UBS | Buy |
| 2023-08-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-26 | 재확인 | Citigroup | Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-05-24 | 재확인 | BofA Securities | Buy |
| 2023-05-24 | 재확인 | UBS | Buy |
| 2023-03-13 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-02-15 | 다운그레이드 | Societe Generale | Hold → Sell |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-09-22 | 업그레이드 | UBS | Neutral → Buy |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2022-03-10 | 개시 | Daiwa Securities | Outperform |
| 2022-01-21 | 업그레이드 | DZ Bank | Hold → Buy |
| 2022-01-03 | 재확인 | Bernstein | Mkt Perform |
| 2021-12-17 | 개시 | Goldman | Neutral |
| 2021-12-16 | 재확인 | BMO Capital Markets | Outperform |
| 2021-12-16 | 재확인 | BofA Securities | Buy |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-10-11 | 업그레이드 | Berenberg | Hold → Buy |
| 2021-09-29 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-08-05 | 업그레이드 | DZ Bank | Hold → Buy |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-06-24 | 재확인 | Cantor Fitzgerald | Overweight |
| 2021-01-19 | 업그레이드 | Mizuho | Neutral → Buy |
| 2020-12-10 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-09-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-04-21 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-04-09 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2019-12-18 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-05-28 | 개시 | Goldman | Buy |
| 2019-04-24 | 업그레이드 | Edward Jones | Hold → Buy |
| 2019-04-11 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-03-12 | 개시 | JP Morgan | Overweight |
| 2019-01-23 | 개시 | UBS | Buy |
| 2018-11-26 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2018-10-31 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | 개시 | Guggenheim | Buy |
| 2018-10-01 | 재확인 | SunTrust | Buy |
| 2018-09-26 | 재개 | JP Morgan | Overweight |
모두보기
일라이 릴리 주식(LLY)의 최신 뉴스
Lilly to appeal after UK agency opposes reimbursement for Alzheimer's drug - Reuters
Wisner Baum: Ninth Circuit Affirms Actos RICO Class Action Certification Against Takeda and Eli Lilly - The Malaysian Reserve
Eli Lilly’s SWOT analysis: stock poised for growth amid challenges in GLP-1 market - Investing.com
Eli Lilly genetic medicine acquisition to address cardiovascular risk - European Pharmaceutical Review
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst - Benzinga
Eli Lilly (LLY) Enters Gene-Editing Space with Verve Therapeutics Acquisition - TipRanks
Eli Lilly (LLY): Bariatric Surgery Outperforms GLP-1 Drugs in We - GuruFocus
Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study - Benzinga
More Than a One Trick Pony, Lilly Feeds Success Back Into Biotech - BioSpace
Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside. - The Globe and Mail
Eli Lilly Stock Dips (18 Jun): Analyzing the Drop and What Traders Should Do Next - Daily Chhattisgarh News
UBS reiterates buy rating on Eli Lilly stock following Verve acquisition - Investing.com
Eli Lilly stock price target maintained at $1,100 by Bernstein on Verve deal - Investing.com Canada
Eli Lilly to Buy Gene Therapy Firm Verve in $1 Billion Deal to Develop Heart Drug - rrdailyherald.com
Lilly to acquire Verve Therapeutics to advance gene editing treatments - World Pharmaceutical Frontiers
Eli Lilly to expand cardiovascular disease pipeline with $1.3bn Verve acquisition - PMLiVE
Eli Lilly (LLY) Moves to Acquire Verve Therapeutics in $1B Deal - GuruFocus
Eli Lilly acquisition of Verve signals renewed interest in gene editing - Investing.com
Lilly Eyes Future of One-Time Cardiovascular Health with $1.3B Verve Therapeutics Acquisition - geneonline.com
Adam Parker of Trivariate Research Recommends Eli Lilly’s Dividend as a Defensive Play - Insider Monkey
In a $1.3B deal, Lilly buys gene editor Verve - BioWorld MedTech
Lilly Agrees To Acquire PCSK9 Base-Editing Partner Verve - insights.citeline.com
Eli Lilly to buy gene-editing biotech Verve for $1.3 billion - The Boston Globe
Eli Lilly Co. to buy gene-editing startup Verve to develop cardiac drugs - upi.com
Eli Lilly lands "bargain" deal to acquire Verve Therapeutics for $1.3bn - Pharmaceutical Technology
Eli Lilly (LLY) 5-Year Growth Surges Over 383%, Showcasing Enduring Strength Beyond Daily Market Moves - Daily Chhattisgarh News
Eli Lilly LLY (NYSE:LLY) Expands Biotech Reach With Verve Deal Talks Dow Jones Industrial Average - Kalkine Media
Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reports - MSN
Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion - MSN
UBS Maintains Price Target on Eli Lilly (LLY) Despite CVS Shift to Wegovy - Insider Monkey
Eli Lilly Bets Big On Gene Editing With Verve Deal - Finimize
Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly - TradingView
Eli Lilly Acquires Verve Therapeutics In $1.3 Billion Deal - Finimize
Lilly acquires cardiovascular genetic medicine company for up to $1.3B - Inside INdiana Business
Eli Lilly to acquire gene-editing specialists focused on CVD for up to $1.3B - Cardiovascular Business
Lilly to acquire Verve in $1B bet on gene editing for heart disease - BioPharma Dive
Eli Lilly to buy Verve Therapeutics for up to $1.3 Billion - Yahoo
Verve Therapeutics Soars 75% After Eli Lilly Buyout - Wall Street Pit
Eli Lilly Expands Gene-Editing Arsenal With Verve Acquisition - Finimize
Lilly adds highest Zepbound doses to DTC offering - STAT
This one-and-done heart-disease treatment just got a $1.3 billion endorsement from Eli Lilly - MSN
Eli Lilly to Buy Gene-Editing Biotech Verve for $1.3 Billion - Bloomberg
Liking what it sees, Lilly to buy base editing partner Verve for $1.3B - FirstWord Pharma
Lilly to buy gene-editing partner Verve for up to $1.3 billion in cardiac care push - Reuters
Eli Lilly Stock Dives Today: A Trader’s Analysis of Key LLY Metrics - Daily Chhattisgarh News
Eli Lilly to acquire gene-editing biotech company Verve Therapeutics for $1.3 billion. Here's why - Mint
Lilly to Acquire Verve Therapeutics for Up to $1.3B - Genetic Engineering and Biotechnology News
Eli Lilly acquires biotech company for USD 1.3bn - medwatch.com
Lilly to buy gene-editing partner Verve for up to US$1.3 billion in cardiac care push - CP24
Verve soars after Eli Lilly announces $1.3 billion acquisition of gene-editing company - Sherwood News
Eli Lilly: The Buy Case Gets Stronger (Rating Upgrade) (NYSE:LLY) - Seeking Alpha
일라이 릴리 (LLY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
일라이 릴리 주식 (LLY) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Yuffa Ilya | EVP & President, LLY Int'l |
May 14 '25 |
Sale |
749.24 |
1,250 |
936,550 |
27,510 |
0.22%
자본화:
|
볼륨(24시간):